Erythropoiesis-stimulating agents on trial: Are higher dosages causing harm?

American Journal of Kidney Diseases

Volumn 61, Issue 1, 2013, Pages 6-8

  Chaknos, C Michael ^a   Berns, Jeffrey S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORBIDITY; POST HOC ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84871240270     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.10.004     Document Type: Editorial

References (13)

1. I. Koulouridis, M. Alfayez, T.A. Trikalinos, E.M. Balk, B.L. Jaber Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis Am J Kidney Dis 61 2013 44 56
2. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590 (Pubitemid 28385655)
3. T.B. Drueke, F. Locatelli, N. Clyne Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
4. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
5. L.A. Szczech, H.X. Barnhart, J.K. Inrig Secondary analysis of the Choir Trial epoetin-alpha dose and achieved hemoglobin outcomes Kidney Int 74 2008 791 798
6. S.D. Solomon, H. Uno, E.F. Lewis Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
7. B.D. Bradbury, M.D. Danese, M. Gleeson, C.W. Critchlow Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL Clin J Am Soc Nephrol 4 2009 630 637
8. M.A. Brookhart, S. Schneeweiss, J. Avorn, B.D. Bradbury, J. Liu, W.C. Winkelmayer Comparative mortality risk of anemia management practices in incident hemodialysis patients JAMA 303 2010 857 864
9. O. Wang, R.D. Kilpatrick, C.W. Critchlow Relationship between epoetin alfa dose and mortality: findings from a marginal structural model Clin J Am Soc Nephrol 5 2010 182 188
10. Y. Zhang, M. Thamer, D. Cotter, J. Kaufman, M.A. Hernan Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States Clin J Am Soc Nephrol 4 2009 638 644
11. S.G. Thompson, J.P. Higgins How should meta-regression analyses be undertaken and interpreted? Stat Med 21 2002 1559 1573 (Pubitemid 34746063)
12. S.C. Palmer, S.D. Navaneethan, J.C. Craig Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease Ann Intern Med 153 2010 23 33
13. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032